

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Versant V Luxco S.a r.l.</u> (Last) (First) (Middle) 15 BOULEVARD F.W. RAFFEISEN (Street) 2411 LUXEMBOURG N4 L-2411 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/02/2019	3. Issuer Name and Ticker or Trading Symbol <u>Aprea Therapeutics, Inc.</u> [APRE]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	12,670	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series B Convertible Preferred Stock	(2)	(2)	Common Stock	1,993,658	(2)	D ⁽¹⁾
Series C Convertible Preferred Stock	(2)	(2)	Common Stock	512,995	(2)	D ⁽¹⁾

1. Name and Address of Reporting Person* <u>Versant V Luxco S.a r.l.</u> (Last) (First) (Middle) 15 BOULEVARD F.W. RAFFEISEN (Street) 2411 LUXEMBOURG N4 L-2411 (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Versant Ventures V, LLC</u> (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Versant Ventures V GP-GP (Canada), Inc.</u> (Last) (First) (Middle) ONE SANSOME STREET SUITE 3630 (City) (State) (Zip)

(Street)
SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Versant Ventures V \(Canada\), L.P.](#)

(Last) (First) (Middle)
ONE SANSOME STREET
SUITE 3630

(Street)
SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Versant Ophthalmic Affiliates I, L.P.](#)

(Last) (First) (Middle)
ONE SANSOME STREET
SUITE 3630

(Street)
SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Versant Affiliates Fund V, L.P.](#)

(Last) (First) (Middle)
ONE SANSOME STREET
SUITE 3630

(Street)
SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Versant Venture Capital V, L.P.](#)

(Last) (First) (Middle)
ONE SANSOME STREET
SUITE 3630

(Street)
SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Versant Venture Capital V \(Canada\), L.P.](#)

(Last) (First) (Middle)
ONE SANSOME STREET
SUITE 3630

(Street)
SAN FRANCISCO CA 94104

(City) (State) (Zip)

Explanation of Responses:

1. Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P., the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.

2. These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") will automatically be converted into shares of the Issuer's Common Stock, on

a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock has no expiration date.

/s/ Versant V Luxco S.a r.l. By: Robin L. Praeger Its: Manager 10/02/2019
/s/ Versant Ventures V, LLC
By: Robin L. Praeger Its: Managing Director 10/02/2019
/s/ Versant Ventures V GP-GP
(Canada), Inc. By: Robin L. Praeger Its: Director 10/02/2019
/s/ Versant Ventures V
(Canada), L.P. By: Versant Ventures V GP-GP (Canada), Inc. Its: General Partner By: Robin L. Praeger Its: Director 10/02/2019
/s/ Versant Venture Capital V
(Canada) LP By: Versant Ventures V (Canada), L.P. Its: General Partner By: Versant Ventures V GP-GP (Canada), Inc. Its: General Partner By: Robin L. Praeger Its: Director 10/02/2019
/s/ Versant Affiliates Fund V, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 10/02/2019
/s/ Versant Ophthalmic Affiliates Fund I, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 10/02/2019
/s/ Versant Venture Capital V, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 10/02/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.